Who are we?
Cyclica harnesses biophysics, bioinformatics and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented structure-based and AI-augmented platform, Ligand Express™ offers novel insight and analysis into a drug's polypharmacology.
By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a target protein structure. We further augment our structural information with AI to drive our biophysical simulations.
Unlike deep-learning approaches that explore the limited space of established drug targets, our technology generates novel predictions that include conventional targets and beyond.
Cyclica's pre-clinical insights and in silico predictions improve current attrition rates of lead therapeutic compounds, improve patient outcomes with fewer side effects, and breathe life back into shelved therapeutics.